Home Business Life Science

Subscribe Now

Life Science

T-Therapeutics out of the block with £48m after just 18 months — T-Therapeutics out of the block with £48m after just 18 months

T-cell receptor therapeutics based on work of Prof Allan Bradley.

Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform

Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform

Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform

It will help hospitals adopts the technology to speed up and improve diagnosis.

University of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementia

University of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementia

University of Cambridge scientists identify potential drug target for major cause of stroke and vascular dementia

They grew small blood vessel-like models in a lab from stem cells.

Genomic surveillance ‘must be applied to antimicrobial resistance’, say researchers

Genomic surveillance ‘must be applied to antimicrobial resistance’, say researchers

Genomic surveillance ‘must be applied to antimicrobial resistance’, say researchers

A group of nearly 100 experts says the technique used to track Covid-19 must be used for AMR.

ViaNautis’s £20m Series A success is breakthrough for polyNaut

ViaNautis’s £20m Series A success is breakthrough for polyNaut

ViaNautis’s £20m Series A success is breakthrough for polyNaut

Company renamed from SomaServe to coincide with development of pioneering platform.

AstraZeneca’s Q3 results show strong momentum – and it invests in once-a-day obesity pill

AstraZeneca’s Q3 results show strong momentum – and it invests in once-a-day obesity pill

AstraZeneca’s Q3 results show strong momentum – and it invests in once-a-day obesity pill

It secured total revenue of $11.49bn in the quarter.

bit.bio pipeline powers up with new expertise joining the SAB

bit.bio pipeline powers up with new expertise joining the SAB

bit.bio pipeline powers up with new expertise joining the SAB

Cell therapy company unveils latest successes.

89 per cent of Abcam shareholders vote for Danaher deal to go ahead

89 per cent of Abcam shareholders vote for Danaher deal to go ahead

89 per cent of Abcam shareholders vote for Danaher deal to go ahead

General meeting secures go-ahead after six months of uncertainty caused by Jonathan Milner bid.

SPT Labtech showcases firefly genomics solution on Melbourn Science Park

SPT Labtech showcases firefly genomics solution on Melbourn Science Park

SPT Labtech showcases firefly genomics solution on Melbourn Science Park

The all-in-one automated solution accelerates research.

New facilities as Sphere Fluidics expands on Granta Park

New facilities as Sphere Fluidics expands on Granta Park

New facilities as Sphere Fluidics expands on Granta Park

Cyto-Mine company’s new labs opened by Deputy Lieutenant of Cambridgeshire.

New CEO takes on role as Eagle Genomics gets £3m funds boost

New CEO takes on role as Eagle Genomics gets £3m funds boost

New CEO takes on role as Eagle Genomics gets £3m funds boost

Anthony Finbow becomes chief evangelist in senior management all-change.

Under the microscope: Danaher deal vs Jonathan Milner plan

Under the microscope: Danaher deal vs Jonathan Milner plan

Under the microscope: Danaher deal vs Jonathan Milner plan

Final pitches ahead of November 6 vote as market compares offers.

New lab part of ‘growing feeling of community’ on Babraham Research Campus

New lab part of ‘growing feeling of community’ on Babraham Research Campus

New lab part of ‘growing feeling of community’ on Babraham Research Campus

LiveL@bs operations manager Ruth Campbell welcomes users to new facility.

Babraham Investor Conference showcases Cambridge’s life science prowess

Babraham Investor Conference showcases Cambridge’s life science prowess

Babraham Investor Conference showcases Cambridge’s life science prowess

New LiveL@bs facility opens up site to all pharma start-ups

First Seqera Sessions in Cambridge proves its value

First Seqera Sessions in Cambridge proves its value

First Seqera Sessions in Cambridge proves its value

Event showcases open science approach for global pharma.

Abcam CEO ‘feels great about process’ ahead of crucial vote

Abcam CEO ‘feels great about process’ ahead of crucial vote

Abcam CEO ‘feels great about process’ ahead of crucial vote

‘It’s important for shareholders to exercise their views,’ says Alan Hirzel of November 6 general meeting.

Zoetis ‘ideal partner’, says PetMedix following acquisition

Zoetis ‘ideal partner’, says PetMedix following acquisition

Zoetis ‘ideal partner’, says PetMedix following acquisition

Babraham Research Campus company focuses on therapeutic antibodies for companion animals.

$15m Series A For Broken String Bioscience’s off-target DNA editing platform

$15m Series A For Broken String Bioscience’s off-target DNA editing platform

$15m Series A For Broken String Bioscience’s off-target DNA editing platform

Cambridge company developing ‘new class of therapies designed in data-driven way’.

Alborada Trust donates £5m to Alzheimer’s Research

Alborada Trust donates £5m to Alzheimer’s Research

Alborada Trust donates £5m to Alzheimer’s Research

Moulton-based charity helping drive forward treatments for dementia.

Cambridge beats San Jose and Oxford to be named as the most intensive science and technology cluster in the world

Cambridge beats San Jose and Oxford to be named as the most intensive science and technology cluster in the world

Cambridge beats San Jose and Oxford to be named as the most intensive science and technology cluster in the world

It tops the 2023 Global Innovation Index.

Rejuvenating! $4m for start-up clock.bio in search for anti-ageing grail

Rejuvenating! $4m for start-up clock.bio in search for anti-ageing grail

Rejuvenating! $4m for start-up clock.bio in search for anti-ageing grail

New Cambridge company founded by Mark Kotter, bit.bio founder and CEO.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More